Crural Repair During Laparoscopic Sleeve Gastrectomy in Patients With a Lax Gastroesophageal Junction (REPAIR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05330910 |
Recruitment Status :
Recruiting
First Posted : April 15, 2022
Last Update Posted : April 15, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Laparoscopic sleeve gastrectomy (LSG) is one of the commonest bariatric procedures. However, it is associated with postoperative gastroesophageal reflux disease (GERD) and erosive esophagitis (EE). The investigators' preliminary study suggests that the incidence of postoperative GERD and EE appears to be correlated with the preoperative presence of a lax gastroesophageal flap valve and hiatal hernia.
Hypothesis/ Aim:
To investigate the impact of a concomitant hiatal hernia repair with LSG on the incidence of postoperative EE.
Significance:
For patients with pre-existing EE, most surgeons will recommend a laparoscopic Roux-en-Y gastric bypass (LRYGB) as their primary bariatric procedure. However, compared to LSG, LRYGB is a technically more demanding procedure with increased morbidity and long term nutritional deficiencies. For asymptomatic patients at risk of postoperative EE due to presence of a hiatal hernia, there is still no consensus on the most appropriate bariatric surgical option. A LSG with a concomitant hiatal hernia repair, if shown to reduce EE postoperatively, may help to expand the pool of patients suitable for LSG in the future.
Methods:
A two center, double-blinded, randomized controlled trial of all patients, undergoing LSG with a preoperative diagnosis of a Hill's grade III gastroesophageal junction, will be randomized to having a concomitant hiatal hernia repair (experimental arm) versus just LSG alone (control arm). Primary outcome measures include 1-year postoperative EE on endoscopy. Secondary outcome measures include postoperative morbidity, blood loss, quality of life and GERD symptoms at 1-year postoperatively.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity Bariatric Surgery Candidate Esophagus Injury Gastroesophageal Reflux | Procedure: Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm Procedure: Laparoscopic sleeve gastrectomy arm | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 96 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This study will be a double institution, double-blinded, randomized controlled trial, involving surgeons from the Upper Gastrointestinal and Bariatric Service, Department of General Surgery, Sengkang General Hospital (SKH) as well as the Department of Upper Gastrointestinal and Bariatric Surgery, Singapore General Hospital (SGH). Randomization will be performed by block randomization, with each block of 4. Block randomization was selected given the small study size, to ensure equal representation in both arms of the study. |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Allocation concealment will be achieved via a central computer-generated random assignment, that will only be made known to the surgeon after the patient is induced on table prior to surgery. Participants from both institutions (SKH, SGH) will be within the same pool for block randomization, to ensure allocation concealment. Access or knowledge about the sequence of the randomization, will not be made known to the PI, Co-Is or mentor, and is only held by protocol administrator. Patient will be blinded to the randomization, and will only be told of the group of allocation at the end of completion of the study, at 1-year, after their postoperative endoscopy at 1-year. Outcomes assessor for primary outcomes at 1-year endoscopy will also be blinded to the initial surgery that was performed. |
Primary Purpose: | Treatment |
Official Title: | A Randomized Controlled Trial Evaluating PAtients With Lax Gastroesophageal Junction to Initial Sleeve Gastrectomy With or Without Concomitant Crural Repair (REPAIR) |
Actual Study Start Date : | April 1, 2022 |
Estimated Primary Completion Date : | April 30, 2027 |
Estimated Study Completion Date : | April 30, 2028 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Laparoscopic sleeve gastrectomy arm
Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
|
Procedure: Laparoscopic sleeve gastrectomy arm
Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after.
Other Names:
|
Experimental: Laparoscopic sleeve gastrectomy with hiatal hernia repair arm
Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
|
Procedure: Laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair arm
Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
Other Names:
|
- Presence or absence of post-operative erosive esophagitis [ Time Frame: 1-year ]Presence or absence of erosive esophagitis on endoscopy
- Degree of Post-operative erosive esophagitis [ Time Frame: 1-year ]Grading of erosive esophagitis on endoscopy, noted as absent, or grade A, B, C or D (based on the Los Angeles classification)
- General Quality of Life Scores [ Time Frame: 3-month, 6-month, 9-month, 1-year ]36-item Short Form Survey. It is a commonly employed questionnaire to assess overall quality of life. It comprises 36 short questions, which directly translates into a 0-100 scoring system. The higher the scores, the better the quality of life.
- Gastroesophageal reflux disease symptoms [ Time Frame: 3-month, 6-month, 9-month, 1-year ]Gastrointestinal Symptom Rating Scale. It is a questionnaire assessing 5 different symptom clusters of gastrointestinal symptoms, namely Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. Each domain has a 7-point graded scale, where 1 represents no symptoms and 7 represents very troublesome symptoms. Hence, the higher the scores in a particular domain, the more troublesome the symptoms. In assessing the endpoint of gastroesophageal reflux disease symptoms, the domain of reflux in the GSRS questionnaire will be evaluated.
- Dysphagia symptoms [ Time Frame: 3-month, 6-month, 9-month, 1-year ]Gastrointestinal Symptom Rating Scale. It is a questionnaire assessing 5 different symptom clusters of gastrointestinal symptoms, namely Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. Each domain has a 7-point graded scale, where 1 represents no symptoms and 7 represents very troublesome symptoms. Hence, the higher the scores in a particular domain, the more troublesome the symptoms. In assessing the endpoint of dysphagia symptoms as the secondary outcome, the domain of indigestion in the GSRS questionnaire will be evaluated.
- Gastrointestinal reflux disease specific quality of life scores [ Time Frame: 3-month, 6-month, 9-month, 1-year ]Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD). The QOLRAD (reflux version) is a 25-item questionnaire specifically focusing on gastroesophageal reflux symptoms. It can be scored based on frequencies, from none of the time to all of the time, for each question. The higher the frequency, the more prevalent the symptoms.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 21-65 years old
- Able to provide informed consent
- Hill's grade III gastroesophageal junction on preoperative endoscopy
- Opted to undergo laparoscopic sleeve gastrectomy as their bariatric procedure
Exclusion Criteria:
- Unable or unwilling to provide informed consent
- Contraindications to laparoscopic sleeve gastrectomy
- Opted not to undergo laparoscopic sleeve gastrectomy
- Had previous upper gastrointestinal surgery
- Had documented erosive esophagitis on preoperative endoscopy
- Had Hill's grade I, II or IV gastroesophageal junction on preoperative endoscopy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05330910
Contact: Koy Min Chue, MBBS, FRCSEd | +65 91196091 | chuekoymin@gmail.com |
Singapore | |
Singapore General Hospital | Recruiting |
Singapore, Singapore, 168753 | |
Contact: Jeremy Tian Hui Tan, MBBS, FRACS | |
Sengkang General Hospital | Recruiting |
Singapore, Singapore, 544886 | |
Contact: Koy Min Chue, MBBS, FRCSEd +65 91196091 chuekoymin@gmail.com |
Principal Investigator: | Baldwin Po Man Yeung, MBChB, FRCS | Sengkang General Hospital | |
Principal Investigator: | Jeremy Tian Hui Tan, MBBS, FRACS | Singapore General Hospital | |
Principal Investigator: | Koy Min Chue, MBBS, FRCSEd | Sengkang General Hospital |
Responsible Party: | Chue Koy Min, Associate Consultant, Sengkang General Hospital |
ClinicalTrials.gov Identifier: | NCT05330910 |
Other Study ID Numbers: |
2022/2028 |
First Posted: | April 15, 2022 Key Record Dates |
Last Update Posted: | April 15, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Unless there is Institutional Ethics Board approval and patient consent |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Obesity Bariatric Surgery Esophagitis Gastroesophageal reflux disease Laparoscopic sleeve gastrectomy |
Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders |
Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |